Physician profile
Alka Tyagi
NPI 1710411608
$649.95
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $131 · 2022: $125.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $157.77 | 2019 | |
| Allergan, INC. | $151.88 | 2019-2020 | |
| Veloxis Pharmaceuticals, INC. | $125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $96.36 | 2019 | |
| Pfizer INC. | $48.46 | 2019 | |
| Boston Scientific Corporation | $17.23 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.93 | 2020 | |
| Nxstage Medical, INC. | $13.54 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.18 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Tyagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.